Item 16. FORM 10-K SUMMARY

3K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.


						2022 Form 10-K \|			110

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, AbbVie Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


AbbVie Inc.
By:	/s/ RICHARD A. GONZALEZ
	Name:	Richard A. Gonzalez
	Title:	Chairman of the Board and Chief Executive Officer
Date:	February 17, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of AbbVie Inc. on February 17, 2023 in the capacities indicated below.


/s/ RICHARD A. GONZALEZ						/s/ SCOTT T. REENTS
Richard A. Gonzalez Chairman of the Board and Chief Executive Officer (Principal Executive Officer)						Scott T. Reents Executive Vice President, Chief Financial Officer (Principal Financial Officer)

/s/ BRIAN L. DURKIN
Brian L. Durkin Vice President, Controller (Principal Accounting Officer)

/s/ ROBERT J. ALPERN, M.D.						/s/ ROXANNE S. AUSTIN
Robert J. Alpern, M.D. Director of AbbVie Inc.						Roxanne S. Austin Director of AbbVie Inc.

/s/ WILLIAM H.L. BURNSIDE						/s/ THOMAS C. FREYMAN
William H.L. Burnside Director of AbbVie Inc.						Thomas C. Freyman Director of AbbVie Inc.

/s/ BRETT J. HART
Brett J. Hart Director of AbbVie Inc.

/s/ MELODY B. MEYER						/s/ EDWARD J. RAPP
Melody B. Meyer Director of AbbVie Inc.						Edward J. Rapp Director of AbbVie Inc.

/s/ REBECCA B. ROBERTS						/s/ GLENN F. TILTON
Rebecca B. Roberts Director of AbbVie Inc.						Glenn F. Tilton Director of AbbVie Inc.

/s/ FREDERICK H. WADDELL
Frederick H. Waddell Director of AbbVie Inc.


111			\| 2022 Form 10-K

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES